US2008124334A1PendingUtilityA1

Isolated Nucleic Acids, Vectors and Host Cells Encoding ErbB3 Antibodies

Assignee: AKITA ROBERTPriority: Mar 27, 1996Filed: Nov 20, 2007Published: May 29, 2008
Est. expiryMar 27, 2016(expired)· nominal 20-yr term from priority
A61P 35/00C07K 2317/55C07K 16/2863G01N 2333/71A61P 25/00C07K 2317/76A61P 29/00G01N 33/74A61K 2039/505C07K 16/32
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.

Claims

exact text as granted — not AI-modified
1 . An antibody which binds to ErbB3 protein and reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3. 
     
     
         2 . The antibody of  claim 1  which further increases the binding affinity of heregulin for ErbB3 protein. 
     
     
         3 . The antibody of  claim 1  which further reduces heregulin-induced ErbB2 activation in the cell. 
     
     
         4 . The antibody of  claim 1  which is a monoclonal antibody. 
     
     
         5 . The antibody of  claim 1  which is humanized. 
     
     
         6 . The antibody of  claim 1  which is human. 
     
     
         7 . The antibody of  claim 1  which is an antibody fragment. 
     
     
         8 . The antibody fragment of  claim 8  which is a Fab. 
     
     
         9 . The antibody of  claim 1  which is labelled. 
     
     
         10 . The antibody of  claim 1  which is immobilized on a solid phase. 
     
     
         11 . An antibody which binds to ErbB3 protein and increases the binding affinity of heregulin for ErbB3 protein. 
     
     
         12 . An antibody which binds to ErbB3 protein and reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3. 
     
     
         13 . An antibody which binds to ErbB3 protein and reduces heregulin binding thereto. 
     
     
         14 . The antibody of  claim 13  which further reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3. 
     
     
         15 . The antibody of  claim 1  which binds to the epitope bound by the 8B8 antibody. 
     
     
         16 . The antibody of  claim 1  which has the complementarity determining regions of the 8B8 antibody. 
     
     
         17 . A composition comprising the antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         18 . A cell line which produces the antibody of  claim 1 . 
     
     
         19 . The cell line of  claim 18  which is a hybridoma cell line producing the 8 B8 antibody. 
     
     
         20 . A method for determining the presence of ErbB3 protein comprising exposing a cell suspected of containing the ErbB3 protein to the antibody of  claim 1  and determining binding of said antibody to the cell. 
     
     
         21 . A kit comprising the antibody of  claim 1  and instructions for using the antibody to detect the ErbB3 protein.

Join the waitlist — get patent alerts

Track US2008124334A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.